COVID-19 Vaccine Sponsors’ Pledge To Wait For Phase III Helps US FDA
The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.
The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.